Cardiovascular Systems Company Profile (NASDAQ:CSII)

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Cardiovascular Systems, Inc. (NASDAQ:CSII) announced its earnings results on Wednesday, May, 3rd. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The company earned $52.10 million during the quarter, compared to analysts' expectations of $51.13 million. Cardiovascular Systems had a negative net margin of 3.72% and a negative return on equity of 4.36%. The business's revenue for the quarter was up 17.1% on a year-over-year basis. During the same period last year, the company posted ($0.31) earnings per share. View Cardiovascular Systems' Earnings History.

Cardiovascular Systems is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Cardiovascular Systems.

Cardiovascular Systems issued an update on its fourth quarter earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of ($0.06)-($0.04) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.03). The company issued revenue guidance of $51.5-$52.5 million, compared to the consensus revenue estimate of $53.79 million.

6 equities research analysts have issued 1 year target prices for Cardiovascular Systems' stock. Their forecasts range from $30.00 to $40.00. On average, they expect Cardiovascular Systems' share price to reach $33.40 in the next twelve months. View Analyst Ratings for Cardiovascular Systems.

Here are some recent quotes from research analysts about Cardiovascular Systems stock:

• 1. According to Zacks Investment Research, "Cardiovascular Systems posted solid second quarter of fiscal 2017, with both earnings and sales ahead of the respective Zacks Consensus Estimate. We are also encouraged by the company’s improving operating expense scenario, driving year-over-year rise in the earnings figure. Per management, the company delivered improved results over the past four quarters, showing major progress in driving revenue growth, while moving toward positive cash flow and profitability. On the flip side, share price trend over the past one month that traded below the broader Medical Products Industry. The company operates in the competitive medical device industry. Additionally, the company expects to witness net loss in the next third quarter a rise in its general and administrative expenses with growth in its business. All these indicate that there is no near term respite from the continuing operating loss structure." (3/16/2017)
• 2. Needham & Company LLC analysts commented, "CSII's F2Q17 revenue and EPS beat consensus. However, F3Q17 revenue and EPS guidance was slightly below consensus. CSII continued on its path to profitability with adjusted EBITDA of $4.6M and cash flow of $5.9M (excluding a one-time $10M payment from Medikit). While revenue growth exceeded 20% Y/ Y for the first time in six quarters, we note that F2Q17 marked the bottom for its revenue growth comps. And although CSII's revenue growth may slow as it faces increasingly difficult comps over the next few quarters, we think it can sustain doubledigit revenue growth. We think that F3Q17 guidance is conservative, and we expect additional revenue and EBITDA upside. Reiterate Buy rating." (1/26/2017)

Cardiovascular Systems saw a increase in short interest in May. As of May 15th, there was short interest totalling 1,278,065 shares, an increase of 3.6% from the April 28th total of 1,233,330 shares. Based on an average trading volume of 657,874 shares, the short-interest ratio is presently 1.9 days.

Some companies that are related to Cardiovascular Systems include Inogen (INGN), Halyard Health (HYH), MiMedx Group (MDXG), CONMED Corporation (CNMD), Asante Solutions (PUMP), K2M Group Holdings (KTWO), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX), AtriCure (ATRC), Intersect ENT (XENT), Meridian Bioscience (VIVO), CryoLife (CRY), Consort Medical plc (CSRT), Landauer (LDR), Antares Pharma (ATRS), Exactech (EXAC), STAAR Surgical Company (STAA) and Invacare Corporation (IVC).

Cardiovascular Systems' management team includes the folowing people:

• Scott R. Ward, Chairman of the Board, President, Chief Executive Officer
• Laurence L. Betterley, Chief Financial Officer
• Kevin J. Kenny, Chief Operating Officer
• Martha Goldberg Aronson, Independent Director
• Scott A. Bartos, Independent Director
• Brent G. Blackey, Independent Director
• Edward M. Brown, Independent Director
• William E. Cohn M.D., Independent Director

Cardiovascular Systems' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (8.49%), Camber Capital Management LLC (5.35%), Champlain Investment Partners LLC (5.34%), Vanguard Group Inc. (5.07%), Cortina Asset Management LLC (2.64%) and Frontier Capital Management Co. LLC (2.54%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Brent G Blackey, Camber Capital Management Llc, David Martin, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn, Robert J Thatcher and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.

Cardiovascular Systems' stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Camber Capital Management LLC, Citadel Advisors LLC, Next Century Growth Investors LLC, JPMorgan Chase & Co., Renaissance Technologies LLC, Driehaus Capital Management LLC and Bogle Investment Management L P DE. Company insiders that have sold Cardiovascular Systems stock in the last year include Alexander Rosenstein, Camber Capital Management Llc, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley and Paul A Koehn. View Insider Buying and Selling for Cardiovascular Systems.

Cardiovascular Systems' stock was purchased by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Vanguard Group Inc., Brown Capital Management LLC, Wellington Management Group LLP, Redwood Investments LLC and Monarch Partners Asset Management LLC. Company insiders that have bought Cardiovascular Systems stock in the last two years include Brent G Blackey, Camber Capital Management Llc and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.

Shares of Cardiovascular Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Cardiovascular Systems stock can currently be purchased for approximately $30.33.